• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Toshiba launches premium performance workstation at ACC conference

Article

A workstation introduced March 11 at the American College of Cardiology conference processes MR cardiac data with such detail that the information rivals what can be obtained from conventional modalities, according to developer Toshiba America Medical Systems.

A workstation introduced March 11 at the American College of Cardiology conference processes MR cardiac data with such detail that the information rivals what can be obtained from conventional modalities, according to developer Toshiba America Medical Systems.

The workstation, FDA clearance for which is imminent, processes MR angiographic data acquired with the company's newly released 1.5T Vantage ZGV, using software that does not require contrast-enhanced data. Specialized algorithms correct for motion artifacts in real-time.

"We are on the verge of having a complete cardiac panel," said Bob Giegerich, director of the MR business unit at Toshiba America Medical Systems. "With this, MR will replace everything - nuclear medicine, ultrasound, and cardiac cath."

Gadolinium-based studies performed on the Vantage ZGV and processed on the new workstation pick up scars in the myocardium so small they may escape detection with thallium studies using conventional gamma cameras, he said. Delayed enhancement data, also obtained with contrast, might help identify patients who will benefit from revascularization following myocardial infarction.

Giegerich touts the Vantage ZGV, which began routine shipping only in the last several weeks, as a premium-performance high-field system, delivering performance in some cases comparable to that of 3T scanners.

The new system and development efforts aimed at enhancing its performance will be profiled March 20 in the next issue of DI SCAN.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.